{"messages":[{"status":"ok","category":"all"}], "collection":[{"title":"Evolution of immunity to SARS-CoV-2","authors":"Wheatley, A. K.; Juno, J. A.; Wang, J. J.; Selva, K. J.; Reynaldi, A.; Tan, H.-X.; Lee, W. S.; Wragg, K. M.; Kelly, H. G.; Esterbauer, R.; Davis, S. K.; Kent, H. E.; Mordant, F. L.; Schlub, T. E.; Gordon, D. L.; Khoury, D. S.; Subbarao, K.; Cromer, D.; Gordon, T. P.; Chung, A. W.; Davenport, M. P.; Kent, S. J.","author_corresponding":"Stephen J Kent","author_corresponding_institution":"University of Melbourne","doi":"10.1101\/2020.09.09.20191205","date":"2020-09-10","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"infectious diseases","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2020\/09\/10\/2020.09.09.20191205.source.xml","abstract":"The durability of infection-induced SARS-CoV-2 immunity has major implications for public health mitigation and vaccine development. Animal studies1,2 and the scarcity of confirmed re-infection3 suggests immune protection is likely, although the durability of this protection is debated. Lasting immunity following acute viral infection requires maintenance of both serum antibody and antigen-specific memory B and T lymphocytes and is notoriously pathogen specific, ranging from life-long for smallpox or measles4, to highly transient for common cold coronaviruses (CCC)5. Neutralising antibody responses are a likely correlate of protective immunity and exclusively recognise the viral spike (S) protein, predominantly targeting the receptor binding domain (RBD) within the S1 sub-domain6. Multiple reports describe waning of S-specific antibodies in the first 2-3 months following infection7-12. However, extrapolation of early linear trends in decay might be overly pessimistic, with several groups reporting that serum neutralisation is stable over time in a proportion of convalescent subjects8,12-17. While SARS-CoV-2 specific B and T cell responses are readily induced by infection6,13,18-24, the longitudinal dynamics of these key memory populations remains poorly resolved. Here we comprehensively profiled antibody, B and T cell dynamics over time in a cohort recovered from mild-moderate COVID-19. We find that binding and neutralising antibody responses, together with individual serum clonotypes, decay over the first 4 months post-infection, as expected, with a similar decline in S-specific CD4+ and circulating T follicular helper (cTFH) frequencies. In contrast, S-specific IgG+ memory B cells (MBC) consistently accumulate over time, eventually comprising a significant fraction of circulating MBC. Modelling of the concomitant immune kinetics predicts maintenance of serological neutralising activity above a titre of 1:40 in 50% of convalescent subjects to 74 days, with probable additive protection from B and T cells. Overall, our study suggests SARS-CoV-2 immunity after infection is likely to be transiently protective at a population level. SARS-CoV-2 vaccines may require greater immunogenicity and durability than natural infection to drive long-term protection.","funder":"NA","published":"10.1038\/s41467-021-21444-5","server":"medRxiv"},{"title":"Evolution of immunity to SARS-CoV-2","authors":"Wheatley, A. K.; Juno, J. A.; Wang, J. J.; Selva, K. J.; Reynaldi, A.; Tan, H.-X.; Lee, W. S.; Wragg, K. M.; Kelly, H. G.; Esterbauer, R.; Davis, S. K.; Kent, H. E.; Mordant, F. L.; Schlub, T. E.; Gordon, D. L.; Khoury, D. S.; Subbarao, K.; Cromer, D.; Gordon, T. P.; Chung, A. W.; Davenport, M. P.; Kent, S. J.","author_corresponding":"Stephen J Kent","author_corresponding_institution":"University of Melbourne","doi":"10.1101\/2020.09.09.20191205","date":"2020-09-11","version":"2","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"infectious diseases","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2020\/09\/11\/2020.09.09.20191205.source.xml","abstract":"The durability of infection-induced SARS-CoV-2 immunity has major implications for public health mitigation and vaccine development. Animal studies1,2 and the scarcity of confirmed re-infection3 suggests immune protection is likely, although the durability of this protection is debated. Lasting immunity following acute viral infection requires maintenance of both serum antibody and antigen-specific memory B and T lymphocytes and is notoriously pathogen specific, ranging from life-long for smallpox or measles4, to highly transient for common cold coronaviruses (CCC)5. Neutralising antibody responses are a likely correlate of protective immunity and exclusively recognise the viral spike (S) protein, predominantly targeting the receptor binding domain (RBD) within the S1 sub-domain6. Multiple reports describe waning of S-specific antibodies in the first 2-3 months following infection7-12. However, extrapolation of early linear trends in decay might be overly pessimistic, with several groups reporting that serum neutralisation is stable over time in a proportion of convalescent subjects8,12-17. While SARS-CoV-2 specific B and T cell responses are readily induced by infection6,13,18-24, the longitudinal dynamics of these key memory populations remains poorly resolved. Here we comprehensively profiled antibody, B and T cell dynamics over time in a cohort recovered from mild-moderate COVID-19. We find that binding and neutralising antibody responses, together with individual serum clonotypes, decay over the first 4 months post-infection, as expected, with a similar decline in S-specific CD4+ and circulating T follicular helper (cTFH) frequencies. In contrast, S-specific IgG+ memory B cells (MBC) consistently accumulate over time, eventually comprising a significant fraction of circulating MBC. Modelling of the concomitant immune kinetics predicts maintenance of serological neutralising activity above a titre of 1:40 in 50% of convalescent subjects to 74 days, with probable additive protection from B and T cells. Overall, our study suggests SARS-CoV-2 immunity after infection is likely to be transiently protective at a population level. SARS-CoV-2 vaccines may require greater immunogenicity and durability than natural infection to drive long-term protection.","funder":"NA","published":"10.1038\/s41467-021-21444-5","server":"medRxiv"}]}